Inclusion Criteria:
* Male or female child, aged 3-6 years (inclusive) at the time of enrollment.
* Caregiver reports the child consumes few vegetables, whole fruit, whole grains, or legumes per week (fewer than two per day on average), consistent with this study's operational definition of low dietary fiber intake.
* Caregiver reports infrequent or difficult bowel movements (constipation) in the child over the past four weeks
* Caregiver reports the child has experienced excess gas, or bloating, over the past four weeks
* Caregiver is willing and able to administer the study product to the child once daily with a meal for 4 weeks, complete digital questionnaires at Baseline, Weeks 1, 2, 3, and End of Study on behalf of the enrolled child, and to facilitate at-home microbiome stool sample collection at Baseline and End of Study and return samples per provided instructions.
* Child is generally healthy, without any acute or chronic condition that would preclude safe participation as determined by caregiver report.
* Caregiver is willing to maintain the child's current diet, sleep patterns, and activity levels throughout the study duration, and to avoid introducing new fiber supplements or probiotic/prebiotic products during the study period.
* Caregiver and child reside in the United States.
* Caregiver is willing and able to provide informed consent; child assent will be obtained where age-appropriate and consistent with IRB requirements.
Exclusion Criteria:
* Known milk allergy, dairy allergy, lactose intolerance, or any known sensitivity to milk-derived products. (The study product's active formulation contains a milk allergen.)
* Child is currently breastfeeding.
* Known allergy or sensitivity to any component of the study product.
* Currently receiving anticoagulant or antiplatelet medications (e.g., warfarin), due to potential interaction with Vitamin K2 contained in the study product.
* Diagnosis of, or current treatment for, any gastrointestinal disease or disorder, including but not limited to: inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, celiac disease, or diagnosed functional gastrointestinal disorders requiring medical management.
* Use of any prescription or over-the-counter laxative, stool softener, antidiarrheal medication, or fiber supplement on a regular basis (≥3 times per week) in the 4 weeks prior to enrollment, or intent to use during the study.
* Use of oral antibiotics or antifungals within 4 weeks prior to enrollment, or anticipated use during the study period.
* Use of any probiotic or prebiotic supplement (other than those naturally occurring in diet) in the 4 weeks prior to enrollment, or intent to use during the study.
* Significant acute illness, including fever, acute gastrointestinal infection, or other acute medical condition at the time of enrollment, or any chronic medical condition, developmental condition, or disability that, in the caregiver's judgment or per clinical guidance, would prevent the child from safely adhering to the study protocol.
* Any planned surgical procedure during the 4-week study period.
* Participation in another research study currently or within the past 30 days, or planned participation in any other research study during this study's duration.